Brief: Immuneering Announces 64% Overall Survival At 12 Months In First-Line Pancreatic Cancer Patients Treated With Atebimetinib + mGnP
07/01/2026 21:28
Jan 7 (Reuters) - Immuneering Corp IMRX.O: IMMUNEERING ANNOUNCES EXCEPTIONAL 64% OVERALL SURVIVAL AT 12 MONTHS IN FIRST-LINE PANCREATIC CANCER PATIENTS TREATED WITH ATEBIMETINIB + MGNP IMMUNEERING CORP - TO DOSE FIRST PATIENT IN PHASE 3 TRIAL MID-2026 Source text: ID:nGNXGg8Xs Further company coverage: IMRX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Immuneering
See all newsImmuneering expects cash runway to fund operations into 2029
Immuneering posts smaller-than-expected Q1 net loss on lower R&D spend
U.S. STOCKS ON THE MOVE-GoPro, Prudential Financial, Whitestone REIT
U.S. STOCKS ON THE MOVE-US airlines, BlackRock, copper miners
U.S. STOCKS ON THE MOVE-Gap, Caterpillar, Solid Biosciences